Thus, considering the exceptional binding kinetic features of A43 compared to human CD48, one key aspect derived from this work is the potential of using A43 to develop novel therapeutic tools to manipulate aberrant immune responses, such as autoimmune diseases. Here, CD48 is linked to autoimmune disease.